{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:12:23Z","timestamp":1793304743399,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary diabetes mellitus (DM) is a common complication of acromegaly, encountered in up to 55% of cases. Vice versa, the prevalence of acromegaly is markedly higher in cohorts of patients with type 2 DM (T2DM). The presence of secondary DM depends primarily on acromegaly status and is associated with increased cardiovascular morbidity, malignancy rate and overall mortality. The principal pathophysiologic mechanism is increased insulin resistance due to excessive lipolysis and altered fat distribution, reflected at the presence of intermuscular fat and attenuated, dysfunctional adipose tissue. Insulin resistance is ascribed to the direct, diabetogenic effects of growth hormone (GH), which prevail over the insulin-sensitizing effects of insulin-like growth factor 1 (IGF-1), probably due to higher glucometabolic potency of GH, IGF-1 resistance, or both. Inversely, GH and IGF-1 act synergistically in increasing insulin secretion. Hyperinsulinemia in portal vein leads to enhanced responsiveness of liver GH receptors and IGF-1 production, pointing towards a mutually amplifying loop between GH-IGF-1 axis and insulin. Secondary DM occurs upon beta cell exhaustion, principally due to gluco-lipo-toxicity. Somatostatin analogues inhibit insulin secretion; especially pasireotide (PASI) impairs glycaemic profile in up to 75% of cases, establishing a separate pathophysiologic entity, PASI-induced DM. In contrast, pegvisomant and dopamine agonizts improve insulin sensitivity. In turn, metformin, pioglitazone and sodium-glucose transporters 2 inhibitors might be disease-modifying by counteracting hyperinsulinemia or acting pleiotropically. Large, prospective cohort studies are needed to validate the above notions and define optimal DM management in acromegaly.<\/jats:p>","DOI":"10.1007\/s12020-023-03339-1","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T20:03:24Z","timestamp":1680725004000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Secondary diabetes mellitus in acromegaly"],"prefix":"10.1007","volume":"81","author":[{"given":"Melpomeni","family":"Moustaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Xekouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Peppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Kalantaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"3339_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"M. Fleseriu, F. Langlois, D.S.T. Lim, E.V. Varlamov, S. Melmed, Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10, 804\u2013826 (2022). https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3339_CR2","doi-asserted-by":"publisher","unstructured":"A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira, R. Pivonello, Acromegaly. Nat. Rev. Dis. Primers. 5, (2019). https:\/\/doi.org\/10.1038\/s41572-019-0071-6","DOI":"10.1038\/s41572-019-0071-6"},{"key":"3339_CR3","first-page":"146","volume":"64","author":"JH Darragh","year":"1951","unstructured":"J.H. Darragh, W.M. Shaw, Acromegaly and Diabetes. Canad. Med. Assoc. J. 64, 146\u2013150 (1951)","journal-title":"Canad. Med. Assoc. J."},{"key":"3339_CR4","first-page":"1106","volume":"87","author":"DA Gordon","year":"1962","unstructured":"D.A. Gordon, F.M. Hill, C. Erzin, Acromegaly: A Review of 100 Cases. Canad. Med. Assoc. J. 87, 1106\u20131109 (1962)","journal-title":"Canad. Med. Assoc. J."},{"key":"3339_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients. Pituitary 17, 81\u201389 (2014). https:\/\/doi.org\/10.1007\/s11102-013-0471-7","journal-title":"Pituitary"},{"key":"3339_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/ec-14-0021","volume":"3","author":"AV Dreval","year":"2014","unstructured":"A.V. Dreval, I.V. Trigolosova, I.V. Misnikova, Y.A. Kovalyova, R.S. Tishenina, I.A. Barsukov, A.V. Vinogradova, B.H.R. Wolffenbuttel, Prevalence of diabetes mellitus in patients with acromegaly. Endocr. Connect 3, 93\u201398 (2014). https:\/\/doi.org\/10.1530\/ec-14-0021","journal-title":"Endocr. Connect"},{"key":"3339_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20945\/2359-3997000000118","volume":"63","author":"YL Li","year":"2019","unstructured":"Y.L. Li, S. Zhang, X.P. Guo, L. Gao, W. Lian, Y. Yao, K. Deng, R.Z. Wang, B. Xing, Correlation analysis between short-term insulin-like growth factor-I and glucose intolerance status after transsphenoidal adenomectomy in acromegalic patients: A large retrospective study from a single center in China. Arch. Endocrinol. Metab. 63, 157\u2013166 (2019). https:\/\/doi.org\/10.20945\/2359-3997000000118","journal-title":"Arch. Endocrinol. Metab."},{"key":"3339_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","volume":"34","author":"A Kreze","year":"2001","unstructured":"A. Kreze, E. Kreze-Spirova, M. Mikulecky, Risk factors for glucose intolerance in acromegaly. Braz. J. Med. Biol. Res. 34, 1429\u20131433 (2001)","journal-title":"Braz. J. Med. Biol. Res."},{"key":"3339_CR9","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1210\/clinem\/dgz317\/5696792","volume":"105","author":"K Hye Park","year":"2020","unstructured":"K. Hye Park, E. Jig Lee, G. Hyeon Seo, C. Ryong Ku, Risk for acromegaly-related comorbidities by sex in Korean acromegaly. J. Clin. Endocrinol. Metab. 105, e1825\u2013e1826 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz317\/5696792","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR10","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1007\/s00701-021-04846-8","volume":"163","author":"S Berkmann","year":"2021","unstructured":"S. Berkmann, J. Brun, P. Schuetz, E. Christ, L. Mariani, B. Mueller, Prevalence and outcome of comorbidities associated with acromegaly. Acta Neurochir. 163, 3171\u20133180 (2021). https:\/\/doi.org\/10.1007\/s00701-021-04846-8","journal-title":"Acta Neurochir."},{"key":"3339_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, E. Sonnet, L. Cazabat, S. Hieronimus, R. Gaillard, A. Enjalbert, I. Raingeard, O. Dupuy, A. Beckers, Diabetes in acromegaly, prevalence, risk factors, and evolution: Data from the French Acromegaly Registry. Eur. J. Endocrinol. 164, 877\u2013884 (2011). https:\/\/doi.org\/10.1530\/EJE-10-1050","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12020-018-1630-4","volume":"61","author":"F Gatto","year":"2018","unstructured":"F. Gatto, G. Trifir\u00f2, F. Lapi, F. Cocchiara, C. Campana, C. Dell\u2019Aquila, C. Ferrajolo, M. Arvigo, C. Cricelli, M. Giusti, D. Ferone, Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine 61, 533\u2013541 (2018). https:\/\/doi.org\/10.1007\/s12020-018-1630-4","journal-title":"Endocrine"},{"key":"3339_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cen.12112","volume":"79","author":"S Vallette","year":"2013","unstructured":"S. Vallette, S. Ezzat, C. Chik, E. Ur, S.A. Imran, S. van Uum, J. Rivera, G. Caspar-Bell, O. Serri, Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin. Endocrinol. 79, 79\u201385 (2013). https:\/\/doi.org\/10.1111\/cen.12112","journal-title":"Clin. Endocrinol."},{"key":"3339_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s42000-020-00191-0","volume":"19","author":"MH AlMalki","year":"2020","unstructured":"M.H. AlMalki, M.M. Ahmad, B.M. Buhary, R. Aljawair, A. Alyamani, A. Alhozali, A. Alshahrani, S. Alzahrani, T. Nasser, W. Alzahrani, H. Raef, M. Aldawish, A. Elkhzaimy, Clinical features and therapeutic outcomes of patients with acromegaly in Saudi Arabia: a retrospective analysis. Hormones 19, 377\u2013383 (2020). https:\/\/doi.org\/10.1007\/s42000-020-00191-0","journal-title":"Hormones"},{"key":"3339_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/EJE-16-0623","volume":"176","author":"E Les\u00e9n","year":"2017","unstructured":"E. Les\u00e9n, D. Granfeldt, A. Houchard, J. Dinet, A. Berthon, D.S. Olsson, I. Bj\u00f6rholt, G. Johannsson, Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: A register-linkage population-based study. Eur. J. Endocrinol. 176, 203\u2013212 (2017). https:\/\/doi.org\/10.1530\/EJE-16-0623","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11102-013-0472-6","volume":"17","author":"I Fukuda","year":"2014","unstructured":"I. Fukuda, N. Hizuka, T. Muraoka, M. Kurimoto, Y. Yamakado, K. Takano, A. Ichihara, Clinical features and therapeutic outcomes of acromegaly during the recent 10 years in a single institution in Japan. Pituitary 17, 90\u201395 (2014). https:\/\/doi.org\/10.1007\/s11102-013-0472-6","journal-title":"Pituitary"},{"key":"3339_CR17","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1210\/jc.2018-00325","volume":"103","author":"B Gonz\u00e1lez","year":"2018","unstructured":"B. Gonz\u00e1lez, G. Vargas, A.L.E. de Los Monteros, V. Mendoza, M. Mercado, Persistence of Diabetes and Hypertension after Multimodal Treatment of Acromegaly. J. Clin. Endocrinol. Metab. 103, 2369\u20132375 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00325","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah, R. Auriemma, A.M. Diallo, A.L. Hulting, D. Ferone, V. Hana, S. Filipponi, C. Sievers, C. Nogueira, C. Fajardo-Monta\u00f1ana, D. Carvalho, V. Hana, G.K. Stalla, M.L. Jaffrain-R\u00e9a, B. Delemer, A. Colao, T. Brue, S.J.C.M.M. Neggers, S. Zacharieva, P. Chanson, A. Beckers, Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database. Endocr. Relat. Cancer 24, 505\u2013518 (2017). https:\/\/doi.org\/10.1530\/ERC-17-0253","journal-title":"Endocr. Relat. Cancer"},{"key":"3339_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"J. Dal, U. Feldt-Rasmussen, M. Andersen, L. Kristensen, P. Laurberg, L. Pedersen, O.M. Dekkers, H.T. S\u00f8rensen, J.O.L. J\u00f8rgensen, Acromegaly incidence, prevalence, complications and long-term prognosis: A nationwide cohort study. Eur. J. Endocrinol. 175, 181\u2013190 (2016). https:\/\/doi.org\/10.1530\/EJE-16-0117","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11102-010-0281-0","volume":"14","author":"PW Rosario","year":"2011","unstructured":"P.W. Rosario, Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14, 217\u2013221 (2011). https:\/\/doi.org\/10.1007\/s11102-010-0281-0","journal-title":"Pituitary"},{"key":"3339_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1507\/endocrj.EJ14-0254","volume":"62","author":"K Suda","year":"2015","unstructured":"K. Suda, H. Fukuoka, K. Iguchi, Y. Hirota, H. Nishizawa, H. Bando, R. Matsumoto, M. Takahachi, K. Sakaguchi, Y. Takahachi, The prevalence of acromegaly in hospitilized patients with type 2 diabetes. Endocr. J. 62, 53\u201359 (2015)","journal-title":"Endocr. J."},{"key":"3339_CR22","doi-asserted-by":"publisher","unstructured":"American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 37, (2014). https:\/\/doi.org\/10.2337\/dc14-S081","DOI":"10.2337\/dc14-S081"},{"key":"3339_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3346\/JKMS.2021.36.E159","volume":"36","author":"SJ Yun","year":"2021","unstructured":"S.J. Yun, J.K. Lee, S.Y. Park, S.O. Chin, Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea. J. Korean Med. Sci. 36, 1\u201310 (2021). https:\/\/doi.org\/10.3346\/JKMS.2021.36.E159","journal-title":"J. Korean Med. Sci."},{"key":"3339_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40618-019-01138-y","volume":"43","author":"A Colao","year":"2020","unstructured":"A. Colao, L.F.S. Grasso, M. di Cera, P. Thompson-Leduc, W.Y. Cheng, H.C. Cheung, M.S. Duh, M.P. Neary, A.M. Pedroncelli, R. Maamari, R. Pivonello, Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J. Endocrinol. Investig. 43, 529\u2013538 (2020). https:\/\/doi.org\/10.1007\/s40618-019-01138-y","journal-title":"J. Endocrinol. Investig."},{"key":"3339_CR25","doi-asserted-by":"publisher","unstructured":"S. Cheng, k. Gomez, O. Serri, C. Chik, S. Ezzat, The role of diabetes in acromegaly associated neoplasia. PLoS ONE. 10, (2015). https:\/\/doi.org\/10.1371\/journal.pone.0127276","DOI":"10.1371\/journal.pone.0127276"},{"key":"3339_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s11102-012-0396-6","volume":"16","author":"D Niculescu","year":"2013","unstructured":"D. Niculescu, M. Purice, M. Coculescu, Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary 16, 168\u2013174 (2013). https:\/\/doi.org\/10.1007\/s11102-012-0396-6","journal-title":"Pituitary"},{"key":"3339_CR27","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"D. Esposito, D.S. Olsson, S. Franz\u00e9n, M. Miftaraj, J. N\u00e5tman, S. Gudbj\u00f6rnsdottir, G. Johannsson, Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly. J. Clin. Endocrinol. Metab. 107, 2483\u20132492 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac400","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol. Metabol. 27, 470\u2013483 (2016). https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","journal-title":"Trends Endocrinol. Metabol."},{"key":"3339_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.21037\/QIMS-20-159","volume":"11","author":"A Nemes","year":"2021","unstructured":"A. Nemes, \u00c1. Korm\u00e1nyos, P. Domsik, A. Kalapos, N. Gyenes, C. Lengyel, Z. Valkusz, Diabetes mellitus deteriorates left ventricular deformation in acromegaly-analysis from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path study. Quant. Imaging Med. Surg. 11, 410\u2013414 (2021). https:\/\/doi.org\/10.21037\/QIMS-20-159","journal-title":"Quant. Imaging Med. Surg."},{"key":"3339_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","volume":"40","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. de Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102\u2013108 (2011). https:\/\/doi.org\/10.1007\/s12020-011-9486-x","journal-title":"Endocrine"},{"key":"3339_CR31","doi-asserted-by":"publisher","unstructured":"H.N. Jang, Y.H. Kim, J.H. Kim, Diabetes Mellitus Predicts Weight Gain After Surgery in Patients with Acromegaly. Front. Endocrinol. 13, (2022). https:\/\/doi.org\/10.3389\/fendo.2022.854931","DOI":"10.3389\/fendo.2022.854931"},{"key":"3339_CR32","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfma.2019.05.007","volume":"118","author":"FY Tseng","year":"2019","unstructured":"F.Y. Tseng, S.T. Chen, J.F. Chen, T.S. Huang, J. Lin, P.W. der, Wang, W. Huey-Herng Sheu, T.C. Chang, Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan Acromegaly Registry. J. Formos. Med. Assoc. 118, 1488\u20131493 (2019). https:\/\/doi.org\/10.1016\/j.jfma.2019.05.007","journal-title":"J. Formos. Med. Assoc."},{"key":"3339_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11102-020-01092-6","volume":"24","author":"B Biagetti","year":"2021","unstructured":"B. Biagetti, A. Aulinas, A. Casteras, S. P\u00e9rez-Hoyos, R. Sim\u00f3, HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary 24, 146\u2013158 (2021). https:\/\/doi.org\/10.1007\/s11102-020-01092-6","journal-title":"Pituitary"},{"key":"3339_CR34","doi-asserted-by":"publisher","unstructured":"D.A. Niculescu, R. Dusceac, A. Caragheorgheopol, N. Popescu, C. Poiana, Disposition Index in Active Acromegaly. Front. Endocrinol. 10, (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00637","DOI":"10.3389\/fendo.2019.00637"},{"key":"3339_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1507\/endocrj.44.617","volume":"44","author":"T Wasada","year":"1997","unstructured":"T. Wasada, K. Aoki, Assessment of Insulin Resistance in Acromegaly Associated with Diabetes Mellitus before and after Transsphenoidal Adenomectomy. Endocr. J. 44, 617\u2013620 (1997)","journal-title":"Endocr. J."},{"key":"3339_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3275\/8964","volume":"36","author":"K Mori","year":"2013","unstructured":"K. Mori, Y. Iwasaki, Y. Kawasaki-Ogita, S. Honjo, Y. Hamamoto, H. Tatsuoka, K. Fujimoto, H. Ikeda, Y. Wada, Y. Takahashi, J. Takahashi, H. Koshiyama, Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: Correlation with serum IGF-I levels. J. Endocrinol. Investig. 36, 853\u2013859 (2013). https:\/\/doi.org\/10.3275\/8964","journal-title":"J. Endocrinol. Investig."},{"key":"3339_CR37","doi-asserted-by":"publisher","unstructured":"A. Ciresi, M.C. Amato, R. Pivonello, E. Nazzari, L.F. Grasso, F. Minuto, D. Ferone, A. Colao, C. Giordano, The metabolic profile in active acromegaly is gender-specific. J. Clin. Endocrinol. Metabol. 98, (2013). https:\/\/doi.org\/10.1210\/jc.2012-2896","DOI":"10.1210\/jc.2012-2896"},{"key":"3339_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N Mo\u00f8ller","year":"2009","unstructured":"N. Mo\u00f8ller, J.O.L. Jo\u00f8rgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152\u2013177 (2009). https:\/\/doi.org\/10.1210\/er.2008-0027","journal-title":"Endocr. Rev."},{"key":"3339_CR39","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","volume":"50","author":"S Nielsen","year":"2001","unstructured":"S. Nielsen, N. M\u00f8ller, J.S. Christiansen, J.O. J\u00f8rgensen, J. Otto Lunde J\u00f8r-gensen, Pharmacological Antilipolysis Restores Insulin Sensitivity During Growth Hormone Exposure. Diabetes 50, 2301\u20132308 (2001)","journal-title":"Diabetes"},{"key":"3339_CR40","doi-asserted-by":"crossref","unstructured":"P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, The Glucose Fatty-Acid Cycle. Its Role in Insulin Sensitivity and the Metabolic Disturbances of Diabetes Mellitus. Lancet 1, 785\u2013789 (1963)","DOI":"10.1016\/S0140-6736(63)91500-9"},{"key":"3339_CR41","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/nejmra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"G.I. Shulman, Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease. N. Engl. J. Med 371, 1131\u20131141 (2014). https:\/\/doi.org\/10.1056\/nejmra1011035","journal-title":"N. Engl. J. Med"},{"key":"3339_CR42","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2007-2780","volume":"93","author":"PU Freda","year":"2008","unstructured":"P.U. Freda, W. Shen, S.B. Heymsfield, C.M. Reyes-Vidal, E.B. Geer, J.N. Bruce, D. Gallagher, Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J. Clin. Endocrinol. Metab. 93, 2334\u20132343 (2008). https:\/\/doi.org\/10.1210\/jc.2007-2780","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR43","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"C.M. Reyes-Vidal, H. Mojahed, W. Shen, Z. Jin, F. Arias-Mendoza, J.C. Fernandez, D. Gallagher, J.N. Bruce, K.D. Post, P.U. Freda, Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J. Clin. Endocrinol. Metab. 100, 2946\u20132955 (2015). https:\/\/doi.org\/10.1210\/jc.2015-1917","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0026-0495(94)90273-9","volume":"43","author":"A Giustina","year":"1994","unstructured":"A. Giustina, E. Bresciani, C. Tassi, A. Girelli, U. Valentini, Effect of Pyridostigmine on the Growth Hormone Response to Growth Hormone-Releasing Hormone in Lean and Obese Type II Diabetic Patients. Metabolism 43, 893\u2013898 (1994)","journal-title":"Metabolism"},{"key":"3339_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2337\/diab.23.6.499","volume":"23","author":"SE Fineberg","year":"1974","unstructured":"S.E. Fineberg, T.J. Merimee, Acute Metabolic Effects of Human Growth Hormone. Diabetes 23, 499\u2013504 (1974)","journal-title":"Diabetes"},{"key":"3339_CR46","doi-asserted-by":"crossref","unstructured":"D. Rabinowitz, G.A. Klassen, K.L. Zierler, Effect of Human Growth Hormone on Muscle and Adipose Tissue Metabolism in the Forearm of Man*. J. Clin. Investig. 44, 51\u201361 (1965)","DOI":"10.1172\/JCI105126"},{"key":"3339_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/diabetes.48.6.1270","volume":"48","author":"ME Griffin","year":"1999","unstructured":"M.E. Griffin, M.J. Marcucci, G.W. Cline, K. Bell, N. Barucci, D. Lee, L.J. Goodyear, E.W. Kraegen, M.F. White, G.I. Shulman, Free Fatty Acid-Induced Insulin Resistance Is Associated With Activation of Protein Kinase C \u03b8 and Alterations in the Insulin Signaling Cascade. Diabetes 48, 1270\u20131274 (1999)","journal-title":"Diabetes"},{"key":"3339_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1172\/JCI5001","volume":"103","author":"A Dresner","year":"1999","unstructured":"A. Dresner, D. Laurent, M. Marcucci, M.E. Griffin, S. Dufour, G.W. Cline, L.A. Slezak, D.K. Andersen, R.S. Hundal, D.L. Rothman, K. Falk Petersen, G.I. Shulman, Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Investig. 103, 253\u2013259 (1999)","journal-title":"J. Clin. Investig."},{"key":"3339_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1152\/ajpendo.00149","volume":"288","author":"N Jessen","year":"2005","unstructured":"N. Jessen, C.B. Djurhuus, J.O.L. J\u00f8rgensen, L.S. Jensen, N. M\u00f8ller, S. Lund, O. Schmitz, Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am. J. Physiol. Endocrinol. Metab. 288, 194\u2013199 (2005). https:\/\/doi.org\/10.1152\/ajpendo.00149","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3339_CR50","first-page":"1012","volume":"74","author":"N Moller","year":"1992","unstructured":"N. Moller, O. Schmitz, J.L. Jorgensen, J. Astrup, J.F. Bak, S.E. Christensen, K. George, M.M: Alberti, Basal-and Insulin-Stimulated Substrate Metabolism in Patients with Active Acromegaly Before and After Adenomectomy*. J. Clin. Endocrinol. Metab. 74, 1012\u20131019 (1992)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR51","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1152\/ajpendo.00374.2006.-The","volume":"292","author":"MB Krag","year":"2007","unstructured":"M.B. Krag, L.C. Gormsen, Z. Guo, J.S. Christiansen, M.D. Jensen, S. Nielsen, J.O. L J\u00f8rgensen, Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. Am. J. Physiol. Endocrinol. Metab. 292, 920\u2013927 (2007). https:\/\/doi.org\/10.1152\/ajpendo.00374.2006.-The","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3339_CR52","doi-asserted-by":"publisher","unstructured":"J. Szendroedi, E. Zwettler, A.I. Schmid, M. Chmelik, G. Pacini, G. Kacerovsky, G. Smekal, P. Nowotny, O. Wagner, C. Schnack, G. Schernthaner, K. Klaushofer, M. Roden, Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly. PLoS ONE. 3, (2008). https:\/\/doi.org\/10.1371\/journal.pone.0003958","DOI":"10.1371\/journal.pone.0003958"},{"key":"3339_CR53","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ajcn\/71.4.885","volume":"71","author":"BH Goodpaster","year":"2000","unstructured":"B.H. Goodpaster, F.L. Thaete, D.E. Kelley, Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am. J. Clin. Nutr. 71, 885\u2013892 (2000)","journal-title":"Am. J. Clin. Nutr."},{"key":"3339_CR54","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/ajcn\/82.6.1210","volume":"82","author":"JB Albu","year":"2005","unstructured":"J.B. Albu, A.J. Kovera, L. Allen, M. Wainwright, E. Berk, N. Raja-Khan, I. Janumala, B. Burkey, S. Heshka, D. Gallagher, Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white nondiabetic women. Am. J. Clin. Nutr. 82, 1210\u20131217 (2005)","journal-title":"Am. J. Clin. Nutr."},{"key":"3339_CR55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ajcn\/86.1.100","volume":"86","author":"JB Albu","year":"2007","unstructured":"J.B. Albu, S. Kenya, Q. He, M. Wainwright, E.S. Berk, S. Heshka, D.P. Kotler, E.S. Engelson, Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am. J. Clin. Nutr. 86, 100\u2013106 (2007)","journal-title":"Am. J. Clin. Nutr."},{"key":"3339_CR56","first-page":"936","volume":"80","author":"M Ottosson","year":"1995","unstructured":"M. Ottosson, K. Vikman-Adolfsson, S. Enerback, A. Elander, P. Bjorntorp, S. Eden, Growth Hormone Inhibits Lipoprotein Lipase Activity in Human Adipose Tissue. J. Clin. Endocrinol. Metab. 80, 936\u2013941 (1995)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR57","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1042\/bj3310815","volume":"331","author":"D Yin","year":"1998","unstructured":"D. Yin, S.D. Clarke, J.L. Peters, T.D. Etherton, Somatotropin-dependent decrease in fatty acid synthase mRNA abundance in 3T3-F442A adipocytes is the result of a decrease in both gene transcription and mRNA stability. Biochem. J. 331, 815\u2013820 (1998)","journal-title":"Biochem. J."},{"key":"3339_CR58","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2004.41","volume":"12","author":"S Yang","year":"2004","unstructured":"S. Yang, H. Mulder, C. Holm, S. Ed\u00e9n, Effects of growth hormone on the function of \u03b2-adrenoceptor subtypes in rat adipocytes. Obes. Res 12, 330\u2013339 (2004). https:\/\/doi.org\/10.1038\/oby.2004.41","journal-title":"Obes. Res"},{"key":"3339_CR59","doi-asserted-by":"publisher","first-page":"E467","DOI":"10.1152\/ajpendo.1992.263.3.E467","volume":"263","author":"M Beauville","year":"1992","unstructured":"M. Beauville, I. Harant, F. Crampes, D. Riviere, M.T. Tauber, J.P. Tauber, M. Garrigues, Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am. J. Physiol. Endocrinol. Metabol. 263, E467\u2013E472 (1992)","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"key":"3339_CR60","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/db06-0299","volume":"56","author":"JP del Rincon","year":"2007","unstructured":"J.P. del Rincon, K. Iida, B.D. Gaylinn, C.E. McCurdy, J.W. Leitner, L.A. Barbour, J.J. Kopchick, J.E. Friedman, B. Draznin, M.O. Thorner, Growth Hormone Regulation of p85\u03b1 Expression and Phosphoinositide 3-Kinase Activity in Adipose tissue: Mechanism for Growth Hormone-Mediated Insulin Resistance. Diabetes 56, 1638\u20131646 (2007). https:\/\/doi.org\/10.2337\/db06-0299","journal-title":"Diabetes"},{"key":"3339_CR61","first-page":"CR685","volume":"8","author":"M Bolanowski","year":"2002","unstructured":"M. Bolanowski, A. Milewicz, B. Bidzi\u0144ska, D. J\u0119drzejuk, J. Daroszewski De, E. Mikulski, Serum leptin levels in acromegaly-a significant role for adipose tissue and fasting insulin\/glucose ratio. Med. Sci. Monit. 8, CR685\u2013CR689 (2002)","journal-title":"Med. Sci. Monit."},{"key":"3339_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1210\/jcem.85.1.6296","volume":"85","author":"SS Damjanovic","year":"2000","unstructured":"S.S. Damjanovic, M.S. Petakov, S. Raicevic, D. Micic, J. Marinkovic, C. Dieguez, F.F. Casanueva, V. Popovic, Serum Leptin Levels in Patients with Acromegaly before and after Correction of Hypersomatotropism by Trans-Sphenoidal Surgery. J. Clin. Endocrinol. Metab. 85, 147\u2013154 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cccn.2004.09.022","volume":"352","author":"P Wiesli","year":"2005","unstructured":"P. Wiesli, R. Bernays, M. Br\u00e4ndle, C. Zwimpfer, H. Seiler, J. Zapf, G. A. Spinas, C. Schmid, Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin. Chim. Acta 352, 175\u2013181 (2005). https:\/\/doi.org\/10.1016\/j.cccn.2004.09.022","journal-title":"Clin. Chim. Acta"},{"key":"3339_CR64","doi-asserted-by":"publisher","unstructured":"S. Gariballa, J. Alkaabi, J. Yasin, A. al Essa, Total adiponectin in overweight and obese subjects and its response to visceral fat loss. BMC Endocr. Disord. 19, (2019). https:\/\/doi.org\/10.1186\/s12902-019-0386-z","DOI":"10.1186\/s12902-019-0386-z"},{"key":"3339_CR65","doi-asserted-by":"publisher","first-page":"E129","DOI":"10.1152\/ajpendo.00068.2015","volume":"310","author":"UA White","year":"2016","unstructured":"U.A. White, J. Maier, P. Zhao, A.J. Richard, J.M. Stephens, The modulation of adiponectin by STAT5-activating hormones. Am. J. Physiol. Endocrinol. Metab. 310, E129\u2013E136 (2016). https:\/\/doi.org\/10.1152\/ajpendo.00068.2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3339_CR66","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1210\/jc.2011-2417","volume":"97","author":"NC Olarescu","year":"2012","unstructured":"N.C. Olarescu, T. Ueland, T. Lekva, T.B. Dahl, B. Halvorsen, P. Aukrust, J. Bollerslev, Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase\/visfatin in active acromegaly. J. Clin. Endocrinol. Metab. 97, 1355\u20131362 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2417","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ghir.2015.07.002","volume":"25","author":"A Ciresi","year":"2015","unstructured":"A. Ciresi, M.C. Amato, G. Pizzolanti, C. Giordano, Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm. IGF Res 25, 240\u2013246 (2015). https:\/\/doi.org\/10.1016\/j.ghir.2015.07.002","journal-title":"Growth Horm. IGF Res"},{"key":"3339_CR68","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tem.2016.02.005","volume":"27","author":"NC Olarescu","year":"2016","unstructured":"N.C. Olarescu, J. Bollerslev, The Impact of Adipose Tissue on Insulin Resistance in Acromegaly. Trends Endocrinol. Metab. 27, 226\u2013237 (2016). https:\/\/doi.org\/10.1016\/j.tem.2016.02.005","journal-title":"Trends Endocrinol. Metab."},{"key":"3339_CR69","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1677\/joe.0.1610383","volume":"161","author":"FP Dominici","year":"1999","unstructured":"F.P. Dominici, D. Cifone, A. Bartke, D. Turyn, Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice. J. Endocrinol. 161, 383\u2013392 (1999)","journal-title":"J. Endocrinol."},{"key":"3339_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1210\/endo-99-3-669","volume":"99","author":"T-Y Tai","year":"1976","unstructured":"T.-Y. Tai, S. Pek, Direct Stimulation by Growth Hormone of Glucagon and Insulin Release from Isolated Rat Pancreas. Endocrinology 99, 669\u2013677 (1976)","journal-title":"Endocrinology"},{"key":"3339_CR71","first-page":"E107","volume":"237","author":"A Sirek","year":"1979","unstructured":"A. Sirek, M. Vranic, V. Sirek, M. Vigas, Z. Policova, Effect of growth hormone on acute glucagon and insulin release. Am. J. Physiol. 237, E107\u2013E112 (1979)","journal-title":"Am. J. Physiol."},{"key":"3339_CR72","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1210\/jcem-51-3-626","volume":"51","author":"ER Trimble","year":"1980","unstructured":"E.R. Trimble, A. Brew Atkinson, K.D. Buchanan, D.R. Hadden, Plasma Glucagon and Insulin Concentrations in Acromegaly. J. Clin. Endocrinol. Metab. 51, 626\u2013631 (1980)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/A:1023321421760","volume":"5","author":"DR Clemmons","year":"2002","unstructured":"D.R. Clemmons, Roles of Insulin-like Growth Factor-I and Growth Hormone in Mediating Insulin Resistance in Acromegaly. Pituitary 5, 181\u2013183 (2002)","journal-title":"Pituitary"},{"key":"3339_CR74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2337\/diab.45.1.91","volume":"45","author":"AC Moses","year":"1996","unstructured":"A.C. Moses, S.C.J. Young, L.A. Morrow, M. O\u2019brien, D.R. Clemmons, Recombinant Human Insulin-like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes. Diabetes 45, 91\u2013100 (1996)","journal-title":"Diabetes"},{"key":"3339_CR75","first-page":"213","volume":"40","author":"S Jin Chan","year":"2000","unstructured":"S. Jin Chan, D.F. Steiner, Insulin Through the Ages: Phylogeny of a Growth Promoting and Metabolic Regulatory Hormone. Am. Zool. 40, 213\u2013222 (2000)","journal-title":"Am. Zool."},{"key":"3339_CR76","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/j.1460-2075.1986.tb04528.x","volume":"5","author":"A Ullrich","year":"1986","unstructured":"A. Ullrich, A. Gray, A.W. Tam, T. Yang-Feng, M. Tsubokawa, C. Collins, W. Henzel, T. le Bon, S. Kathuria, E. Chen, S. Jacobs, U. Francke, J. Ramachandran, Y. Fujita-Yamaguchi, Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5, 2503\u20132512 (1986)","journal-title":"EMBO J."},{"key":"3339_CR77","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.2337\/diab.39.9.1028","volume":"39","author":"GL Dohm","year":"1990","unstructured":"G.L. Dohm, C.W. Elton, M.S. Raju, N.D. Mooney, R. Dimarchi, W.J. Pories, E.G. Flickinger, S.M. Atkinson, J.F. Caro, jGF-l-Stimulated Glucose Transport in Human Skeletal Muscle and IGF-I Resistance in Obesity and NIDDM. Diabetes 39, 1028\u20131032 (1990)","journal-title":"Diabetes"},{"key":"3339_CR78","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2337\/diab.38.10.1217","volume":"38","author":"MK Sinha","year":"1989","unstructured":"M.K. Sinha, C. Buchanan, N. Leggett, L. Martin, P.G. Khazanie, R. Dimarchi, W.J. Pories, J.F. Caro, Mechanism of IGF-I-Stimulated Glucose Transport in Human Adipocytes Demonstration of Specific IGF-I Receptors Not Involved in Stimulation of Glucose Transport. Diabetes 38, 1217\u20131242 (1989)","journal-title":"Diabetes"},{"key":"3339_CR79","doi-asserted-by":"publisher","first-page":"T187","DOI":"10.1530\/JME-18-0076","volume":"61","author":"RD Kineman","year":"2018","unstructured":"R.D. Kineman, M. del Rio-Moreno, A. Sarmento-Cabral, 40 years of IGF1: Understanding the tissue-specific roles of IGF1\/IGF1R in regulating metabolism using the Cre\/loxP system. J. Mol. Endocrinol. 61, T187\u2013T198 (2018). https:\/\/doi.org\/10.1530\/JME-18-0076","journal-title":"J. Mol. Endocrinol."},{"key":"3339_CR80","first-page":"2911","volume":"83","author":"M Federici","year":"1998","unstructured":"M. Federici, O. Porzio, D. Lauro, P. Borboni, B. Giovannone, L. Zucaro, M. Letizia Hribal, G. Sesti,, Increased Abundance of Insulin\/Insulin-Like Growth Factor-I Hybrid Receptors in Skeletal Muscle of Obese Subjects Is Correlated with In Vivo Insulin Sensitivity.*. J. Clin. Endocrinol. Metab. 83, 2911\u20132913 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR81","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1172\/JCI119117","volume":"98","author":"M Federici","year":"1996","unstructured":"M. Federici, L. Zucaro, O. Porzio, R. Massoud, P. Borboni, D. Lauro, G. Sesti, Increased Expression of Insulin\/Insulin-like Growth Factor-I Hybrid Receptors in Skeletal Muscle of Noninsulin-dependent Diabetes Mellitus Subjects. J. Clin. Investig 98, 2887\u20132893 (1996)","journal-title":"J. Clin. Investig"},{"key":"3339_CR82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0303-7207(97)00185-8","volume":"135","author":"M Federici","year":"1997","unstructured":"M. Federici, O. Porzio, L. Zucaro, B. Giovannone, P. Borboni, M.A. Marini, D. Lauro, G. Sesti, Increased abundance of insulin\/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol. Cell. Endocrinol. 135, 41\u201347 (1997)","journal-title":"Mol. Cell. Endocrinol."},{"key":"3339_CR83","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1006\/bbrc.2001.5904","volume":"288","author":"CM Halleux","year":"2001","unstructured":"C.M. Halleux, M. Takahashi, M.L. Delporte, R. Detry, T. Funahashi, Y. Matsuzawa, S.M. Brichard, Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem. Biophys. Res. Commun. 288, 1102\u20131107 (2001). https:\/\/doi.org\/10.1006\/bbrc.2001.5904","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3339_CR84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000112590","volume":"69","author":"H Fukuoka","year":"2008","unstructured":"H. Fukuoka, Y. Takahashi, K. Iida, T. Kudo, H. Nishizawa, M. Imanaka, R. Takeno, G. Iguchi, K. Takahashi, Y. Okimura, H. Kaji, K. Chihara, Low serum IGF-I\/GH ratio is associated with abnormal glucose tolerance in acromegaly. Horm. Res 69, 165\u2013171 (2008). https:\/\/doi.org\/10.1159\/000112590","journal-title":"Horm. Res"},{"key":"3339_CR85","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2337\/diabetes.50.5.1110","volume":"50","author":"S Yakar","year":"2001","unstructured":"S. Yakar, J.-L. Liu, A.M. Fernandez, Y. Wu, A.V. Schally, J. Frystyk, S.D. Chernausek, W. Mejia, D. le Roith, Liver-Specific igf-1 Gene Deletion Leads to Muscle Insulin Insensitivity. Diabetes 50, 1110\u20131118 (2001)","journal-title":"Diabetes"},{"key":"3339_CR86","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1172\/JCI200417763","volume":"113","author":"S Yakar","year":"2004","unstructured":"S. Yakar, J. Setser, H. Zhao, B. Stannard, M. Haluzik, V. Glatt, M.L. Bouxsein, J.J. Kopchick, D. LeRoith, Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J. Clin. Invest 113, 96\u2013105 (2004)","journal-title":"J. Clin. Invest"},{"key":"3339_CR87","doi-asserted-by":"publisher","unstructured":"J.A.M.J.L. Janssen, Mechanisms of putative IGF-I receptor resistance in active acromegaly. Growth Horm. IGF Res. 52, (2020). https:\/\/doi.org\/10.1016\/j.ghir.2020.101319","DOI":"10.1016\/j.ghir.2020.101319"},{"key":"3339_CR88","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1210\/jcem-30-3-288","volume":"30","author":"SE Fineberg","year":"1970","unstructured":"S.E. Fineberg, T.J. Merimee, D. Rabinowitz, P.J. Edgar, Insulin Secretion in Acromegaly. J. Clin. Endocrinol. 30, 288 (1970)","journal-title":"J. Clin. Endocrinol."},{"key":"3339_CR89","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1172\/jci200215276","volume":"110","author":"S Xuan","year":"2002","unstructured":"S. Xuan, T. Kitamura, J. Nakae, K. Politi, Y. Kido, P.E. Fisher, M. Morroni, S. Cinti, M.F. White, P.L. Herrera, D. Accili, A. Efstratiadis, Defective insulin secretion in pancreatic \u03b2 cells lacking type 1 IGF receptor. J. Clin. Invest 110, 1011\u20131019 (2002). https:\/\/doi.org\/10.1172\/jci200215276","journal-title":"J. Clin. Invest"},{"key":"3339_CR90","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1172\/JCI45027DS1","volume":"121","author":"Y Wu","year":"2011","unstructured":"Y. Wu, C. Liu, H. Sun, A. Vijayakumar, P.R. Giglou, R. Qiao, J. Oppenheimer, S. Yakar, D. Leroith, Growth hormone receptor regulates \u03b2 cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J. Clin. Invest 121, 2422\u20132426 (2011). https:\/\/doi.org\/10.1172\/JCI45027DS1","journal-title":"J. Clin. Invest"},{"key":"3339_CR91","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.2337\/diabetes.50.2007.S25","volume":"50","author":"JH Nielsen","year":"2001","unstructured":"J.H. Nielsen, E.D. Galsgaard, A. M\u00f8ldrup, N. Friedrichsen, N. Billestrup, J.A. Hansen, Y.C. Lee, C. Carlsson, Regulation of \u03b2-Cell Mass by Hormones and Growth Factors. Diabetes 50, S25\u2013S29 (2001)","journal-title":"Diabetes"},{"key":"3339_CR92","doi-asserted-by":"publisher","unstructured":"Z. Wang, L. Gao, X. Guo, C. Feng, K. Deng, W. Lian, M. Feng, X. Bao, B. Xing, Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study of 64 Cases From a Large Pituitary Center in China. Front. Endocrinol. 10, (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00736","DOI":"10.3389\/fendo.2019.00736"},{"key":"3339_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12020-018-1745-7","volume":"63","author":"W He","year":"2019","unstructured":"W. He, L. Yan, M. Wang, Q. Li, M. He, Z. Ma, Z. Ye, Q. Zhang, Y. Zhang, N. Qiao, Y. Lu, H. Ye, B. Lu, X. Shou, Y. Zhao, Y. Li, S. Li, Z. Zhang, M. Shen, Y. Wang, Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases. Endocrine 63, 27\u201335 (2019). https:\/\/doi.org\/10.1007\/s12020-018-1745-7","journal-title":"Endocrine"},{"key":"3339_CR94","doi-asserted-by":"publisher","unstructured":"V.S. Shekhawat, S. Bhansali, P. Dutta, K.K. Mukherjee, K. Vaiphei, R. Kochhar, S.K. Sinha, N. Sachdeva, A.V. Kurpad, Bhat, K., Mudaliar, S., Bhansali, A. Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and \u03b2-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly. Sci. Rep. 9, (2019). https:\/\/doi.org\/10.1038\/s41598-019-41887-7","DOI":"10.1038\/s41598-019-41887-7"},{"key":"3339_CR95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/EJE-13-0060","volume":"169","author":"N Yoshida","year":"2013","unstructured":"N. Yoshida, H. Goto, H. Suzuki, K. Nagasawa, A. Takeshita, M. Okubo, M. Miyakawa, Y. Mori, N. Fukuhara, H. Nishioka, S. Yamada, Y. Takeuchi, Ketoacidosis as the initial clinical condition in nine patients with acromegaly: A review of 860 cases at a single institute. Eur. J. Endocrinol. 169, 127\u2013132 (2013). https:\/\/doi.org\/10.1530\/EJE-13-0060","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR96","doi-asserted-by":"publisher","unstructured":"P. Palakawong, R. Arakaki, Diabetic Ketoacidosis in Acromegaly: A Case Report. Endocr. Pract. 1\u201315 (2012). https:\/\/doi.org\/10.4158\/ep12189.cr","DOI":"10.4158\/ep12189.cr"},{"key":"3339_CR97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.diabres.2017.08.023","volume":"134","author":"J Weiss","year":"2017","unstructured":"J. Weiss, A.J. Wood, J.D. Zajac, M. Grossmann, S. Andrikopoulos, E.I. Ekinci, Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use. Diabetes Res. Clin. Pract. 134, 29\u201337 (2017). https:\/\/doi.org\/10.1016\/j.diabres.2017.08.023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"3339_CR98","doi-asserted-by":"publisher","first-page":"68","DOI":"10.17925\/EE.2021.17.1.68","volume":"1","author":"M Singla","year":"2021","unstructured":"M. Singla, J.K. Saini, Diabetes Mellitus of Pituitary Origin: A Case Report. Eur. Endocrinol. 1, 68 (2021). https:\/\/doi.org\/10.17925\/EE.2021.17.1.68","journal-title":"Eur. Endocrinol."},{"key":"3339_CR99","doi-asserted-by":"publisher","unstructured":"S.I. Chisalita, J. Ludvigsson, Insulin-like growth factor-1 at diagnosis and during subsequent years in adolescents with type 1 diabetes. J Diabetes Res. (2018). https:\/\/doi.org\/10.1155\/2018\/8623560","DOI":"10.1155\/2018\/8623560"},{"key":"3339_CR100","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ghir.2016.03.002","volume":"29","author":"K Suda","year":"2016","unstructured":"K. Suda, R. Matsumoto, H. Fukuoka, G. Iguchi, Y. Hirota, H. Nishizawa, H. Bando, K. Yoshida, Y. Odake, M. Takahashi, K. Sakaguchi, W. Ogawa, Y. Takahashi, The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm. IGF Res 29, 4\u201310 (2016). https:\/\/doi.org\/10.1016\/j.ghir.2016.03.002","journal-title":"Growth Horm. IGF Res"},{"key":"3339_CR101","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1210\/jc.2007-2350","volume":"93","author":"J Frystyk","year":"2008","unstructured":"J. Frystyk, R.A. Ritzel, J. Maubach, M. B\u00fcsing, R. L\u00fcck, J. Klempnauer, W. Schmiegel, M.A. Nauck, Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: Impact on glucose regulatory hormones and the growth hormone\/insulin-like growth factor-I axis. J. Clin. Endocrinol. Metab. 93, 1758\u20131766 (2008). https:\/\/doi.org\/10.1210\/jc.2007-2350","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR102","doi-asserted-by":"publisher","unstructured":"D.R. Wijayaratne, M.H. Arambewela, C. Dalugama, C., Wijesundera, D., Somasundaram, N., Katulanda, P.: Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: A case report. J. Med. Case Rep. 9, (2015). https:\/\/doi.org\/10.1186\/s13256-015-0736-z","DOI":"10.1186\/s13256-015-0736-z"},{"key":"3339_CR103","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1507\/endocrj.K06-083","volume":"54","author":"D Jun Lim","year":"2007","unstructured":"D. Jun Lim, H. Sang Kwon, J. Hyoung Cho, S. Hee Kim, Y. Hee Choi, K.H. Yoon, B. Yun Cha, K. Woo Lee, H. Young Son, S. Koo Kang, Acromegaly Associated with Type 2 Diabetes Showing Normal IGF-1 Levels under Poorly Controlled Glycemia. Endocr. J. 54, 537\u2013541 (2007)","journal-title":"Endocr. J."},{"key":"3339_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-13-0438","volume":"171","author":"M Droste","year":"2014","unstructured":"M. Droste, J. Domberg, M. Buchfelder, K. Mann, A. Schwanke, G. Stalla, C.J. Strasburger, Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur. J. Endocrinol. 171, 59\u201368 (2014). https:\/\/doi.org\/10.1530\/EJE-13-0438","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","volume":"48","author":"U Kumar","year":"1999","unstructured":"U. Kumar, R. Sasi, S. Suresh, A. Patel, M. Thangaraju, P. Metrakos, S.C. Patel, Y.C. Patel, Subtype-Selective Expression of the Five Somatostatin Receptors (hSSTR1-5) in Human Pancreatic Islet Cells A Quantitative Double-Label Immunohistochemical A n a l y s i s. Diabetes 48, 77\u201385 (1999)","journal-title":"Diabetes"},{"key":"3339_CR106","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","volume":"23","author":"A Giustina","year":"2014","unstructured":"A. Giustina, G. Mazziotti, F. Maffezzoni, V. Amoroso, A. Berruti, Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Exp. Opin. Investig. Drugs 23, 1619\u20131635 (2014). https:\/\/doi.org\/10.1517\/13543784.2014.942728","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"3339_CR107","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500\u20131508 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2332","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR108","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11102-016-0724-3","volume":"19","author":"BT Sagvand","year":"2016","unstructured":"B.T. Sagvand, S. Khairi, A. Haghshenas, B. Swearingen, N.A. Tritos, K.K. Miller, A. Klibanski, L.B. Nachtigall, Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary 19, 437\u2013447 (2016). https:\/\/doi.org\/10.1007\/s11102-016-0724-3","journal-title":"Pituitary"},{"key":"3339_CR109","doi-asserted-by":"publisher","unstructured":"M. Shen, M. Wang, W. He, M. He, N. Qiao, Z. Ma, Z. Ye, Q. Zhang, Y. Zhang, Y. Yang, Y. Cai, Y. Abuduoreyimu, Y. Lu, B. Lu, X. Shou, Y. Wang, H. Ye, Y. Li, S. Li, Y. Zhao, X. Cao, Z. Zhang, Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study. Int. J. Endocrinol. (2018). https:\/\/doi.org\/10.1155\/2018\/3015854","DOI":"10.1155\/2018\/3015854"},{"key":"3339_CR110","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1210\/jc.2008-2627","volume":"94","author":"A Colao","year":"2009","unstructured":"A. Colao, R.S. Auriemma, S. Savastano, M. Galdiero, L.F.S. Grasso, G. Lombardi, R. Pivonello, Glucose tolerance and somatostatin analog treatment in acromegaly: A 12-month study. J. Clin. Endocrinol. Metab. 94, 2907\u20132914 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2627","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR111","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11102-011-0361-9","volume":"15","author":"E Couture","year":"2012","unstructured":"E. Couture, V. Bongard, J.C. Maiza, A. Bennet, P. Caron, Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15, 518\u2013525 (2012). https:\/\/doi.org\/10.1007\/s11102-011-0361-9","journal-title":"Pituitary"},{"key":"3339_CR112","doi-asserted-by":"publisher","first-page":"e00033","DOI":"10.1002\/edm2.33","volume":"2","author":"D Cappellani","year":"2019","unstructured":"D. Cappellani, C. Urbani, C. Sardella, I. Scattina, G. Marconcini, I. Lupi, L. Manetti, C. Marcocci, F. Bogazzi, Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinol. Diabetes Metab. 2, e00033 (2019). https:\/\/doi.org\/10.1002\/edm2.33","journal-title":"Endocrinol. Diabetes Metab."},{"key":"3339_CR113","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jdi.12675","volume":"9","author":"S Tanaka","year":"2018","unstructured":"S. Tanaka, A. Haketa, S. Yamamuro, T. Suzuki, H. Kobayashi, Y. Hatanaka, T. Ueno, N. Fukuda, M. Abe, A. Yoshino, M. Soma, Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report. J. Diabetes Investig. 9, 223\u2013225 (2018). https:\/\/doi.org\/10.1111\/jdi.12675","journal-title":"J. Diabetes Investig."},{"key":"3339_CR114","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Res\u00e9ndiz, M. Ruffin, Y. Chen, M. Sheppard, Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791\u2013799 (2014). https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR115","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875\u2013884 (2014). https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3339_CR116","doi-asserted-by":"publisher","unstructured":"M. Gadelha, M. Bex, M., Colao, A., Pedroza Garc\u00eda, E.M., Poiana, C., Jimenez-Sanchez, M., Yener, S., Mukherjee, R., Bartalotta, A., Maamari, R., Raverot, G. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients with Acromegaly Inadequately Controlled with First-Generation Somatostatin Analogs. Front. Endocrinol. (Lausanne). 10, (2020). https:\/\/doi.org\/10.3389\/fendo.2019.00931","DOI":"10.3389\/fendo.2019.00931"},{"key":"3339_CR117","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","volume":"64","author":"S Tahara","year":"2017","unstructured":"S. Tahara, M. Murakami, T. Kaneko, A. Shimatsu, Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr. J. 64, 735\u2013747 (2017)","journal-title":"Endocr. J."},{"key":"3339_CR118","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"M.R. Gadelha, F. Gu, M.D. Bronstein, T.C. Brue, M. Fleseriu, I. Shimon, A.J. van der Lely, S. Ravichandran, A. Kandra, A.M. Pedroncelli, A.A.L. Colao, Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr. Connect 9, 1178\u20131190 (2020). https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr. Connect"},{"key":"3339_CR119","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"M. Stelmachowska-Bana\u015b, I. Czajka-Oraniec, A. Tomasik, W. Zgliczy\u0144ski, Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25, 180\u2013190 (2022). https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"key":"3339_CR120","doi-asserted-by":"publisher","unstructured":"M.D. Bronstein, M. Fleseriu, S. Neggers, A. Colao, M. Sheppard, F. Gu, C.C. Shen, M. Gadelha, A.J. Farrall, K.H. Res\u00e9ndiz, M. Ruffin, Y.M. Chen, P. Freda, Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: Crossover extension to a randomized, double-blind, Phase III study. BMC Endocr. Disord. 16, (2016). https:\/\/doi.org\/10.1186\/s12902-016-0096-8","DOI":"10.1186\/s12902-016-0096-8"},{"key":"3339_CR121","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013). https:\/\/doi.org\/10.1210\/jc.2013-1771","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR122","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12020-017-1386-2","volume":"58","author":"E Tarasco","year":"2017","unstructured":"E. Tarasco, P. Seebeck, S. Pfundstein, A.F. Daly, P.J. Eugster, A.G. Harris, E. Grouzmann, T.A. Lutz, C.N. Boyle, Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine 58, 124\u2013133 (2017). https:\/\/doi.org\/10.1007\/s12020-017-1386-2","journal-title":"Endocrine"},{"key":"3339_CR123","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"C.E. Higham, S. Rowles, D. Russell-Jones, A.M. Umpleby, P.J. Trainer, Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 2459\u20132463 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2086","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR124","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","volume":"19","author":"I Bernabeu","year":"2016","unstructured":"I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escol\u00e1, J.A. Garc\u00eda-Arn\u00e9s, M. Marazuela, P. Jonsson, N. Mir, M. Garc\u00eda Vargas; Spanish ACROSTUDY Group, Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19, 127\u2013137 (2016). https:\/\/doi.org\/10.1007\/s11102-015-0691-0","journal-title":"Pituitary"},{"key":"3339_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"T. Brue, A. Lindberg, A. Jan van der Lely, A.C. Akerblad, M. Koltowska-H\u00e4ggstr\u00f6m, R. Gomez, M. Droste, J. Hey-Hadavi, C.J. Strasburger, C: Camacho-H\u00fcbner, Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63, 563\u2013572 (2019). https:\/\/doi.org\/10.1007\/s12020-018-1792-0","journal-title":"Endocrine"},{"key":"3339_CR126","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1210\/jc.2015-1678","volume":"100","author":"J Guevara-Aguirre","year":"2015","unstructured":"J. Guevara-Aguirre, A.L. Rosenbloom, P. Balasubramanian, E. Teran, M. Guevara-Aguirre, C. Guevara, P. Procel, I. Alfaras, R. de Cabo, S. di Biase, L. Narvaez, J. Saavedra, V.D. Longo, GH receptor deficiency in ecuadorian adults is associated with obesity and enhanced insulin sensitivity. J. Clin. Endocrinol. Metab. 100, 2589\u20132596 (2015). https:\/\/doi.org\/10.1210\/jc.2015-1678","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR127","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ghir.2015.08.002","volume":"28","author":"J Guevara-Aguirre","year":"2016","unstructured":"J. Guevara-Aguirre, P. Procel, C. Guevara, M. Guevara-Aguirre, V. Rosado, E. Teran, Despite higher body fat content, Ecuadorian subjects with Laron syndrome have less insulin resistance and lower incidence of diabetes than their relatives. Growth Horm. IGF Res 28, 76\u201378 (2016). https:\/\/doi.org\/10.1016\/j.ghir.2015.08.002","journal-title":"Growth Horm. IGF Res"},{"key":"3339_CR128","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"A. Muhammad, A.J. van der Lely, P.J.D. Delhanty, A.H.G. Dallenga, I.K. Haitsma, J.A.M.J.L. Janssen, S.J.C.M.M. Neggers, Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J. Clin. Endocrinol. Metab. 103, 586\u2013595 (2018). https:\/\/doi.org\/10.1210\/jc.2017-02017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR129","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.12.029","volume":"109","author":"F Lopez Vicchi","year":"2016","unstructured":"F. Lopez Vicchi, G.M. Luque, B. Brie, J.P. Nogueira, I. Garcia Tornadu, D. Becu-Villalobos, Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol. Res. 109, 74\u201380 (2016). https:\/\/doi.org\/10.1016\/j.phrs.2015.12.029","journal-title":"Pharmacol. Res."},{"key":"3339_CR130","doi-asserted-by":"publisher","unstructured":"R.S. Auriemma, D. de Alcubierre, R. Pirchio, R. Pivonello, A. Colao, Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front. Endocrinol. 10, (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00327","DOI":"10.3389\/fendo.2019.00327"},{"key":"3339_CR131","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2265.1981.tb00690.x","volume":"15","author":"CM Feek","year":"1981","unstructured":"C.M. Feek, J.S. Bevan, S. Taylor, N.S. Brown, J.D. Baird, The Effect of Bromocryptine on Insulin Secretion and Glucose Tolerance in Patients with Acromegaly. Clin. Endocrinol. 15, 473\u2013478 (1981)","journal-title":"Clin. Endocrinol."},{"key":"3339_CR132","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2007-1018923","volume":"14","author":"T Chiba","year":"1982","unstructured":"T. Chiba, K. Chihara, N. Minamitani, B. Goto, S. Kadowaki, T. Taminato, S. Matsukura, T. Fujita, Effect of Long Term Bromocriptine Treatment on Glucose Intolerance in Acromegaly. Horm. Metabol. Res. 14, 57\u201361 (1982)","journal-title":"Horm. Metabol. Res."},{"key":"3339_CR133","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/BF00186626","volume":"71","author":"H Rau","year":"1993","unstructured":"H. Rau, P.-H. Althoff, K. Schmidt, K. Badenhoop, K.H. Usadel, Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion*. Clin. Investig. 71, 372\u2013378 (1993)","journal-title":"Clin. Investig."},{"key":"3339_CR134","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ghir.2010.05.004","volume":"20","author":"J Roemmler","year":"2010","unstructured":"J. Roemmler, B. Steffin, B. Gutt, H.J. Schneider, C. Sievers, M. Bidlingmaier, J. Schopohl, The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm. IGF Res 20, 338\u2013344 (2010). https:\/\/doi.org\/10.1016\/j.ghir.2010.05.004","journal-title":"Growth Horm. IGF Res"},{"key":"3339_CR135","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","volume":"23","author":"H Pijl","year":"2000","unstructured":"H. Pijl, S. Ohashi, M. Matsuda, Y. Miyazaki, A. Mahankali, V. Kumar, R. Pipek, P. Iozzo, J.L. Lancaster, A.H. Cincotta, R.A. de Fronzo, Bromocryptine. A novel approach to the treatment of type 2 diabetes. Diabetes Care 23, 1154\u20131161 (2000)","journal-title":"Diabetes Care"},{"key":"3339_CR136","doi-asserted-by":"publisher","unstructured":"S. St\u00f6rmann, J. Schopohl, Drug treatment strategies for secondary diabetes in patients with acromegaly. Exp. Opin. Pharmacother. 1883\u20131895 (2020). https:\/\/doi.org\/10.1080\/14656566.2020.1789098","DOI":"10.1080\/14656566.2020.1789098"},{"key":"3339_CR137","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40618-015-0404-6","volume":"39","author":"MG Baroni","year":"2016","unstructured":"M.G. Baroni, F. Giorgino, V. Pezzino, C. Scaroni, A. Avogaro, Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing\u2019s syndrome and acromegaly. J. Endocrinol. Invest 39, 235\u2013255 (2016). https:\/\/doi.org\/10.1007\/s40618-015-0404-6","journal-title":"J. Endocrinol. Invest"},{"key":"3339_CR138","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3275\/7685","volume":"35","author":"VM Cambuli","year":"2012","unstructured":"V.M. Cambuli, M. Galdiero, M. Mastinu, F. Pigliaru, R.S. Auriemma, A. Ciresi, R. Pivonello, M. Amato, C. Giordano, S. Mariotti, A. Colao, M.G. Baroni, Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia. J. Endocrinol. Invest 35, 154\u2013159 (2012). https:\/\/doi.org\/10.3275\/7685","journal-title":"J. Endocrinol. Invest"},{"key":"3339_CR139","first-page":"87","volume":"48","author":"M Gradi\u0161er","year":"2007","unstructured":"M. Gradi\u0161er, M. Matovinovi\u0107, M. Vrkljan, Decrease in Growth Hormone and Insulin-like Growth Factor (IGF)-1 Release and Amelioration of Acromegaly Features after Rosiglitazone Treatment of Type 2 Diabetes Mellitus in a Patient with Acromegaly Case Report Case Report. Croat. Med. J. 48, 87\u201391 (2007)","journal-title":"Croat. Med. J."},{"key":"3339_CR140","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1464-5491.2004.01299.x","volume":"21","author":"A Watanabe","year":"2004","unstructured":"A. Watanabe, F. Komine, K. Nirei, K. Tamura, K. Nabe, N. Aiba, S. Kamoshida, M. Otsuka, H. Okubo, M. Kanou, S. Sawada, T. Uchiyama, S. Nakamurat, Y. Arakawa, A case of secondary diabetes mellitus with acromegaly improved by pioglitazone. Diab. Med 21, 1049\u20131050 (2004). https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01299.x","journal-title":"Diab. Med"},{"key":"3339_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","volume":"73","author":"A Zaina","year":"2021","unstructured":"A. Zaina, Y. Grober, A. Abid, E. Arad, E. Golden, S. Badarny, Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes\u2014a case series and literature review. Endocrine 73, 65\u201370 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02718-w","journal-title":"Endocrine"},{"key":"3339_CR142","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1210\/jc.2017-00082","volume":"102","author":"M Quarella","year":"2017","unstructured":"M. Quarella, D. Walser, M. Br\u00e4ndle, J.Y. Fournier, S. Bilz, Rapid Onset of Diabetic Ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J. Clin. Endocrinol. Metab. 102, 1451\u20131453 (2017). https:\/\/doi.org\/10.1210\/jc.2017-00082","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3339_CR143","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tem.2018.11.007","volume":"30","author":"Z Adnan","year":"2019","unstructured":"Z. Adnan, Sodium Glucose Co-transporter Inhibitors in Patients with Acromegaly and Diabetes. Trends Endocrinol. Metab. 30, 77\u201379 (2019). https:\/\/doi.org\/10.1016\/j.tem.2018.11.007","journal-title":"Trends Endocrinol. Metab."},{"key":"3339_CR144","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"S.L. Samson, F. Gu, U. Feldt-Rasmussen, S. Zhang, Y. Yu, P. Witek, P. Kalra, A.M. Pedroncelli, P. Pultar, N. Jabbour, M. Paul, M. Bolanowski, Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24, 887\u2013903 (2021). https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"key":"3339_CR145","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"AP Heaney","year":"2003","unstructured":"A.P. Heaney, M. Fernando, S. Melmed, PPAR-\u03b3 receptor ligands: Novel therapy for pituitary adenomas. J. Clin. Invest 111, 1381\u20131388 (2003). https:\/\/doi.org\/10.1172\/JCI200316575","journal-title":"J. Clin. Invest"},{"key":"3339_CR146","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MAJ.0b013e31827ad893","volume":"345","author":"Y Kashiwagi","year":"2013","unstructured":"Y. Kashiwagi, Y. Mizuno, E. Harada, M. Shono, S. Morita, M. Yoshimura, M. Yano, H. Yasue, Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. Am. J. Med Sci. 345, 497\u2013500 (2013). https:\/\/doi.org\/10.1097\/MAJ.0b013e31827ad893","journal-title":"Am. J. Med Sci."},{"key":"3339_CR147","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1530\/EJE-20-0795","volume":"184","author":"M Albertelli","year":"2021","unstructured":"M. Albertelli, E. Nazzari, A. Dotto, L.F. Grasso, S. Sciallero, R. Pirchio, A. Rebora, M. Boschetti, R. Pivonello, S.R. Bitti, A.A.L. Colao, D. Ferone, Possible protective role of metformin therapy on colonic polyps in acromegaly: An exploratory cross-sectional study. Eur. J. Endocrinol. 184, 423\u2013429 (2021). https:\/\/doi.org\/10.1530\/EJE-20-0795","journal-title":"Eur. J. Endocrinol."},{"key":"3339_CR148","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"M.J. Davies, V.R. Aroda, B.S. Collins, R.A. Gabbay, J. Green, N.M. Maruthur, S.E. Rosas, S. del Prato, C. Mathieu, G. Mingrone, P. Rossing, T. Tankova, A. Tsapas, J.B. Buse, Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753\u20132786 (2022). https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03339-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T08:23:13Z","timestamp":1685780593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03339-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":148,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03339-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}